Quick Answer
Pharmagreen Biotech Inc. reported Cash and Equivalents of $25.3 thousand for fiscal year 2021.
Pharmagreen Biotech Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2021 | $25.3K | +107.4% |
| 2020 | $12.2K | -80.5% |
| 2019 | $62.7K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| June 30, 2022 | $24.3K | +26.2% | +696.8% |
| March 31, 2022 | $3.0K | -77.5% | -88.0% |
| September 30, 2021 | $25.3K | +107.4% | +31.6% |
| June 30, 2021 | $19.2K | — | +42.2% |
| March 31, 2021 | $13.5K | — | +10.8% |
| September 30, 2020 | $12.2K | — | — |
- Pharmagreen Biotech Inc. showed an increase of +107.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2021 period, Pharmagreen Biotech Inc.’s cash and equivalents has declined by 59.6% (from $62.7 thousand to $25.3 thousand).
- The most recent figure is from Pharmagreen Biotech Inc.’s fiscal year 2021 report (Form 10-K), filed with the SEC on December 29, 2021.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: